<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685824</url>
  </required_header>
  <id_info>
    <org_study_id>2020410013068</org_study_id>
    <nct_id>NCT04685824</nct_id>
  </id_info>
  <brief_title>Visual Telerehabilitation in AMD Patients</brief_title>
  <official_title>Visual Rehabilitation in Macular Degeneration: a Pilot Study on Biofeedback Training and Home-based Mobile Virtual-reality Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Reber</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following the degeneration of the macula and the loss of central vision, the patients&#xD;
      naturally relocate the fixation point for high visual acuity peripherally, in an eccentric&#xD;
      and healthy part of the retina (PRL), to compensate for visual impairments. However, in many&#xD;
      cases, the PRL lands on a sub-optimal retinal area and becomes useless. Modern low-vision&#xD;
      rehabilitation procedures for AMD patients include biofeedback training (BFT) to relocate the&#xD;
      PRL to a healthy retinal patch and acquire better fixation skills. This study seeks to&#xD;
      combine BFT with home-based immersive virtual-reality audiovisual stimulation and measure&#xD;
      feasibility and potential effectiveness on oculomotor control and visual perception.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of home-based IVR audiovisual stimulation</measure>
    <time_frame>18 months</time_frame>
    <description>Feasibility objectives for our pilot study to be considered successful:&#xD;
Number of patients completing the stimulation protocol: ≥ 13 out of 16 patients (81%) per group.&#xD;
Number of IVR sessions performed by the patients to consider the stimulation protocol complete: ≥ 13 sessions out of 16 (81%).&#xD;
Number of consecutive virtual-reality induced symptoms and effects (VRISE) scores &lt; 25: ≤ 3 per patient during the treatment period.&#xD;
Number of patient drop-outs due to cybersickness (discomfort symptoms experienced in VR): ≤ 3 (19%) during the treatment period.&#xD;
Number of randomized patients per week: ≥ 3 patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>from baseline to end of follow-up at 7 months</time_frame>
    <description>Change from baseline at 4 weeks, 1 month and 6 months:&#xD;
- Best Corrected Visual Acuity, distance and near vision (range 20/12.5 to &lt;20/1000, higher score = better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Sensitivity</measure>
    <time_frame>from baseline to end of follow-up at 7 months</time_frame>
    <description>Change from baseline at 4 weeks,1 month and 6 months:&#xD;
- Mean retinal sensitivity (Macular Integrity Assessment, MAIA microperimetry - score: 0 dB to 36 dB, higher score = better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fixation stability</measure>
    <time_frame>from baseline to end of follow-up at 7 months</time_frame>
    <description>Change from baseline at 4 weeks,1 month and 6 months:&#xD;
- Mean fixation stability (Macular Integrity Assessment, MAIA microperimetry - range 0.02 sq.deg. to 40.0 sq.deg., lowest score = better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>from baseline to end of follow-up at 7 months</time_frame>
    <description>Change from baseline at 4 weeks, 1 month and 6 months:&#xD;
- Mean contrast sensitivity (Functional Acuity Contrast Test, FACT - range 0.48 cyc./deg. to 2.41 cyc./deg., higher score = better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reading Speed</measure>
    <time_frame>from baseline to end of follow-up at 7 months</time_frame>
    <description>Change from baseline at 4 weeks,1 month and 6 months:&#xD;
- Mean reading speed (Minnesota Low Vision Reading test, MNREAD - range 0 word/minute to 280 word/minute, higher score = better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Scores</measure>
    <time_frame>from baseline to end of follow-up at 7 months</time_frame>
    <description>Change from baseline at 4 weeks,1 month and 6 months:&#xD;
- Quality of life scores (Veteran's Affairs Low Vision Questionnaire, VA-LVQ 48 - range -31.5 to +26.6, higher score = better outcome)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Biofeedback Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biofeedback training (BFT): 1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks. 1 session per week for 4 weeks (4 sessions total).&#xD;
30 min daily reading at home for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biofeedback Training + Immersive VR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biofeedback training (BFT) [1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks], 1 session per week for 4 weeks (4 sessions total).&#xD;
30 min daily reading at home for 4 weeks&#xD;
Immersive virtual-reality stimulation (IVR) [1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks], 1 session every 2 days for 4 weeks (14 sessions total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biofeedback Training</intervention_name>
    <description>Audiovisual stimulation</description>
    <arm_group_label>Biofeedback Training</arm_group_label>
    <arm_group_label>Biofeedback Training + Immersive VR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Immersive Virtual-Reality</intervention_name>
    <description>Audiovisual stimulation</description>
    <arm_group_label>Biofeedback Training + Immersive VR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dry-AMD.&#xD;
&#xD;
          -  BCVA &gt; 20/160.&#xD;
&#xD;
          -  Ability to follow the visual and auditory stimuli and training instructions.&#xD;
&#xD;
          -  Auditory test positive at 50Hz 25-60dBHL.&#xD;
&#xD;
          -  Home Wi-Fi access.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Wet AMD.&#xD;
&#xD;
          -  Both eyes with media opacity that impairs microperimetry testing.&#xD;
&#xD;
          -  Inability to perform during testing and training.&#xD;
&#xD;
          -  Psychoactive drugs consumption.&#xD;
&#xD;
          -  3 consecutive VRISE scores &lt; 25 at inclusion.&#xD;
&#xD;
          -  History of vertigo or dizziness&#xD;
&#xD;
          -  Prior vision rehabilitation interventions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Reber, PhD</last_name>
    <phone>416-634-7937</phone>
    <email>michel.reber@uhnresearch.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Daibert-Nido, MD</last_name>
    <email>monica.nido@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Krembil Research Institute/Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 0S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Reber</last_name>
      <email>michael.reber@uhnresearch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Monica Daibert-Nido</last_name>
      <email>monica.nido@uhn.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Michael Reber</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Visual rehabilitation</keyword>
  <keyword>Oculus Go</keyword>
  <keyword>Virtual-reality</keyword>
  <keyword>Biofeedback</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

